⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199990 | 0.79 | — | — | |
| SCHEMBL1786411 | 0.76 | CHRM5 (0.46) | — | |
| SCHEMBL1377298 | 0.72 | CHRM5 (0.48) | — | |
| SCHEMBL7321483 | 0.71 | CHRM5 (0.60) | — | |
| SCHEMBL18740713 | 0.71 | — | — | |
| SCHEMBL5171785 | 0.71 | CHRM5 (0.52) | — | |
| Hydrochloric Acid SCHEMBL7331633 | 0.69 | CHRM5 (0.57) | — | |
| SCHEMBL8804357 | 0.68 | CHRM5 (0.59) | — | |
| SCHEMBL19288793 | 0.67 | CHRM5 (0.48) | — | |
| SCHEMBL2225387 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251387-A | Mixed lineage kinase inhibitors and methods of use thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2024-06-25 | — | — | CN | disclosed |
| CN-103819416-A | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC | 2014-05-28 | — | — | CN | disclosed |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| CN-103202842-A | Methods Of Treating By Inhibiting With Quinaxoline Inhibitors Of P13k-alpha | EXELIXIS INC | 2013-07-17 | — | — | CN | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| CN-101959516-B | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2013-05-08 | — | — | CN | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |